Zydus Lifesciences Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Zydus Lifesciences Ltd filed with BSE on 01 Sept 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Zydus Lifesciences reported consolidated revenue of Rs. 271.5 billion for FY2025-26, growth of 17% over the previous year, with an EBITDA margin of 31.2%. Management described growth across India formulations, international markets, and Consumer Wellness, along with new entries into MedTech and biosimilars, and disclosed a post-year-end share buyback of up to Rs. 1,100 crore at Rs. 1,260 per share. Management also said the company expects high-teen revenue growth in FY27, supported by its Indian and international businesses, new product launches, and integration of recent acquisitions.
Numbers mentioned
Consolidated revenue: Rs. 271.5 billion (FY2025-26)
p. 5
“Consolidated revenues reached Rs. 271.5 billion, representing growth of 17% over the previous year.”
Chairman, page 5 of the filed PDF · View the filing
EBITDA margin: 31.2% (FY2025-26)
p. 5
“The Company also delivered higher operating profit and profitability levels, with an EBITDA margin at 31.2%.”
Chairman, page 5 of the filed PDF · View the filing
R&D spend as % of revenue: approximately 8% (FY2025-26)
p. 5
“We maintained our investment in research and development at approximately 8% of our revenues during the year and consistent with our longstanding commitment to scientific innovation and the development of future healthcare solutions.”
Chairman, page 5 of the filed PDF · View the filing
Renewable energy share of energy mix: 42%
p. 6
“Renewable energy now contributes 42% of our overall energy mix, and greenhouse gas intensity has declined by 19% over the past two years.”
Chairman, page 6 of the filed PDF · View the filing
Share buyback size: up to Rs. 1,100 crore at Rs. 1,260 per share
p. 6
“the Board approved a share buyback of up to Rs. 1,100 crore at Rs. 1,260 per share.”
Chairman, page 6 of the filed PDF · View the filing
Dividend: Re. 1/- per share (100%) (FY2025-26)
p. 8
“Declaration of dividend @ Re. 1/- (which is 100%) for the financial year 2025-2026.”
Company Secretary, page 8 of the filed PDF · View the filing
Global workforce: around 30,000 people, including more than 1,500 R&D scientists
p. 6
“Our global workforce of around 30,000 people, including more than 1,500 R&D scientists is not a mere statistic; it represents the core driving force behind our mission.”
Chairman, page 6 of the filed PDF · View the filing
Consolidated revenue (shareholder-cited figure): Rs. 27,148 crore vs Rs. 23,242 crore previous year (FY2025-26 vs FY2024-25)
p. 18
“In consolidated accounts, our revenue is grown to Rs. 27,148/- crore, previous year it was Rs. 23,242/- crore.”
Mr. Om Prakash Kejriwal, page 18 of the filed PDF · View the filing
EPS: Rs. 50.09 vs Rs. 44.97 previous year (FY2025-26 vs FY2024-25)
p. 18
“And our EPS has grown to Rs. 50.09/- on face value Re. 1/-, previous year was Rs. 44.97/-.”
Mr. Om Prakash Kejriwal, page 18 of the filed PDF · View the filing
North American formulation revenue: Rs. 11,682 crores
p. 19
“amongst the North American formulation revenues of Rs. 11,682 crores, how much revenue is contributed by our generics and the speciality business portfolio?”
Mr. Samrat Sarkar, page 19 of the filed PDF · View the filing
ANDAs filed per year: 30+
p. 25
“We have 30+ ANDAs that we file every year.”
Dr. Sharvil Patel, Managing Director, page 25 of the filed PDF · View the filing
ANDA approvals: about 35-40
p. 25
“And we do see about 35-40 approvals that we are seeing come through.”
Dr. Sharvil Patel, Managing Director, page 25 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — high-teen revenue growth · FY27
stated as an aspiration by Chairman
p. 6
“We enter FY27 confident in delivering high-teen revenue growth, powered by the momentum of our Indian and international businesses, new product launches, and disciplined integration of our recent acquisitions.”
Chairman, page 6 of the filed PDF · View the filing
Saroglitazar US launch — US launch for Primary Biliary Cholangitis · Q4 FY2027
stated conditionally by Chairman
p. 4
“Subject to approval, a US launch is planned for Q4 FY2027.”
Chairman, page 4 of the filed PDF · View the filing
Debt repayment — pay out all the debts · next two years
stated as an aspiration by Chairman
p. 25
“we believe in the next two years, we should be able to pay out all the debts.”
Chairman, page 25 of the filed PDF · View the filing
Debt repayment — pay down debt without major acquisition · two years
stated conditionally by Dr. Sharvil Patel, Managing Director
p. 27
“if without any major acquisition we can see comfortably in two years being able to pay down this debt that we have today.”
Dr. Sharvil Patel, Managing Director, page 27 of the filed PDF · View the filing
Dividend payout policy — around 30% of profits
stated firmly by Chairman
p. 23
“our policy is to continue to giving at least around close to 30% of our profits to dividend and we will continue to do that policy going forward as well.”
Chairman, page 23 of the filed PDF · View the filing
India business growth — better than market growth · coming years
stated firmly by Dr. Sharvil Patel, Managing Director
p. 26
“we are committed to showing better than market growth in the coming years with the pipeline of products that we have.”
Dr. Sharvil Patel, Managing Director, page 26 of the filed PDF · View the filing
Saroglitazar US launch (Saro) — Saroglitazar launch in the US · FY 28
stated as an aspiration by Dr. Sharvil Patel, Managing Director
p. 27
“we also hope to see Saroglitazar launch coming in the coming next year FY 28 in the US and build onto that momentum.”
Dr. Sharvil Patel, Managing Director, page 27 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Acquisitions will continue where they add market access or capability, not simply for value addition.
Answered by Chairman
Asked by Mr. Jaydip Bakshi: Are there further acquisitions or joint ventures planned for growth?
p. 23
“it is over policy to acquire but it will only be acquired where we can get additional market access or capability and that’s a strategy we follow.”
Chairman, page 23 of the filed PDF · View the filing
Management said combined dividend and buyback reward is higher than last year and payout policy will continue.
Answered by Chairman
Asked by Mr. Hiranand Kotwani: How will the company reward minority shareholders given low dividend?
p. 23
“I think if you compare calculate our dividend plus buyback, I think our reward is higher than last year, and our policy is to continue to giving at least around close to 30% of our profits to dividend and we will continue to do that policy going forward as well.”
Chairman, page 23 of the filed PDF · View the filing
Management said the US market carries regular pricing, regulatory and tariff challenges, but the company is competent to manage them.
Answered by Chairman
Asked by Mr. Badri Vishal Bajaj: How is the company addressing US regulatory and pricing pressure?
p. 24
“The pricing, regulatory and tariff, are the three things which is a regular challenge to be there in US market. But our Company and our people are competent enough to address this”
Chairman, page 24 of the filed PDF · View the filing
Management said there has been no change in plant leadership as the FDA track record is good.
Answered by Chairman
Asked by Mr. Parikshit Gohil: Have there been changes in plant-level leadership at facilities issued Form 483?
p. 24
“There are no change in plant leadership as our track record with FDI is good. And there is no plan to change the plant leadership at this moment.”
Chairman, page 24 of the filed PDF · View the filing
Management pointed to a resilient supply chain and portfolio management to handle pricing and regulatory changes in the US.
Answered by Dr. Sharvil Patel, Managing Director
Asked by Mr. Narendra Porwal / Mr. Vinod Agarwal: How will the company handle US tariffs on generic exports?
p. 26
“the most important part of the US is to have a resilient supply chain both from API, KSM and supply point of view.”
Dr. Sharvil Patel, Managing Director, page 26 of the filed PDF · View the filing
Management said Zydus has a significant share of the semaglutide molecule and expects to be the largest-selling semaglutide injectable brand in India.
Answered by Dr. Sharvil Patel, Managing Director
Asked by Mr. Samrat Sarkar: How much revenue is expected from the generic semaglutide portfolio in FY27?
p. 26
“Amongst all the companies we put our shares together with Zydus innovative semaglutide, we will be the largest selling semaglutide injectable brand in India.”
Dr. Sharvil Patel, Managing Director, page 26 of the filed PDF · View the filing
Management said Zydus has integrated the Assertio business and will continue to run and sell its products.
Answered by Dr. Sharvil Patel, Managing Director
Asked by Mr. Om Prakash Kejriwal: Does Assertio become a subsidiary after the takeover, and will it remain listed on Nasdaq?
p. 25
“we obviously have integrated that business now already and we hope that we continue to believe that Zydus in its current operations will run and sell the products Rolvedon.”
Dr. Sharvil Patel, Managing Director, page 25 of the filed PDF · View the filing
Risks flagged
Water logging and drainage issues at Pharmez and surrounding facilities during heavy rain
p. 24
“between Moraiya to Bavla, everything was flooded this time. And the water was not going.”
Chairman, page 24 of the filed PDF · View the filing
US market pricing, regulatory and tariff pressures
p. 24
“The pricing, regulatory and tariff, are the three things which is a regular challenge to be there in US market.”
Chairman, page 24 of the filed PDF · View the filing
Security concerns at Zydus Pharmez facility raised by a shareholder
p. 15
“people are openly smoking inside the facility.”
Mr. Parikshit Gohil, page 15 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.